IMNN READ THE FULL IMNN RESEARCH REPORT Business Update First Site Activated for Phase 3 OVATION 3 Trial of IMNN-001 in ...

Stacy Lindborg; President, Chief Executive Officer and Board Director; Imunon Inc. Presentation. Operator. Good morning. My name is Dave, and I will be your operator ...

Imunon, Inc. ( NASDAQ: IMNN) Q1 2025 Earnings Conference Call May 12, 2025 11:00 AM ET Peter Vozzo - ICR Healthcare, Investor Relations Stacy Lindborg - President & Chief Executive Officer Douglas ...

IMUNON initiates Phase 3 OVATION 3 study for IMNN-001 in advanced ovarian cancer; Phase 2 data accepted for ASCO presentation. IMUNON, Inc. has initiated the first trial site for its Phase 3 ...

Analysts estimate that Imunon will report an earnings per share (EPS) of $-0.36. Investors in Imunon are eagerly awaiting the ...

First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at ...

Q1 2025 Management View President & CEO Stacy Lindborg announced the initiation of the first clinical site in Imunon's ...

Imunon Inc (IMNN) reported a narrower-than-expected loss for the first quarter of 2025, with earnings per share (EPS) of -$0.28 against a forecast of -$0.3575. The company’s stock price responded ...

"IMUNON continues to make significant strides towards our goal of transforming the treatment landscape for women with advanced ovarian cancer. In 2024, our Phase 1/2 OVATION 2 Study delivered ...

Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit ...

Imunon Inc (IMNN) reported a narrower-than-expected loss for the first quarter of 2025, with earnings per share (EPS) of -$0.28 against a forecast of -$0.3575. The company’s stock price ...

The first trial site is Washington University School of Medicine, and IMUNON is currently initiating additional trial sites and working with investigators to begin enrolling study participants.